SOURCE: Amazon Biotech, Inc.

March 30, 2007 16:05 ET

Amazon Biotech Inc. in Early Negotiations With Major Pharmaceutical Companies

Joint Venture Agreement to Focus on Clinical Studies and Marketing of Company's Anti-HIV Drug, AMZ-0026

NEW YORK, NY -- (MARKET WIRE) -- March 30, 2007 -- Amazon Biotech, Inc. (OTC BB: AMZB) (FRANKFURT: B2D) announced that it has secured the services of Mr. Stanley Fass to negotiate a joint venture agreement between Amazon Biotech and major pharmaceutical companies.

Amazon Biotech has entered in negotiations with major pharmaceutical companies for funding of future studies and marketing of the company's anti-HIV drug, AMZ0026 which has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.

Mr. Fass had previously been with Intec Pharma Ltd. as vice president business development where he successfully negotiated a joint venture with Glaxo SmithKline (GSK). He also served as President of Perio Products, Ltd. for 12 years where he successfully negotiated joint venture agreements with Astra Pharmaceuticals, Procter & Gamble, Carter-Wallace, Colgate, Novartis, AL Pharma, IofI in Japan, amongst others.

Dr. Mechael Kanovsky, CEO of Amazon Biotech, said, "The negotiations are in early stages and there is no assurance that any of these negotiations will lead to a joint venture deal. However, we are pleased that a number of large pharmaceutical companies have shown preliminary interest in our phytopharmaceutical drug product."

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans, upon funding, to initiate Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. All negotiations that are currently going on with major pharmaceutical companies are in the early stages and may not lead to any agreements or contracts. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at:

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information

  • Contact:
    LC Group
    Rick Lutz
    (404) 261-1196